Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 201 to 210 of 294

TitleType
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema ID6137Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All